United States-based Gilead Sciences is planning to introduce authorised generic versions of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg) in the United States, it was reported yesterday.

The treatments for chronic hepatitis C virus (HCV) will be introduced in the US, through a newly created subsidiary, Asegua Therapeutics.

The authorised generics will be introduced at a list price of USD24,000 for the most common course of therapy and will be offered in January 2019.